Long-term Safety Follow-up Study of Patients Having Received HepaStem (SAF001)

Key facts

Sponsor

Cellaion SA

Principal Investigator

Françoise Smets, MD

Cliniques universitaires Saint-Luc (Belgium)

Enrollment

9 enrolled

Eligibility

23 years · All sexes

Timeline

2013 – 2019

Study locations (1)

• Promethera Biosciences, Mont-Saint-Guibert, Belgium

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Crigler-Najjar syndrome

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT03466463
  Gene Therapy for Severe Crigler Najjar Syndrome
  Genethon

See all trials for Crigler-Najjar syndrome →